GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Current Ratio

THRD (Third Harmonic Bio) Current Ratio : 42.50 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Third Harmonic Bio's current ratio for the quarter that ended in Sep. 2024 was 42.50.

Third Harmonic Bio has a current ratio of 42.50. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Third Harmonic Bio's Current Ratio or its related term are showing as below:

THRD' s Current Ratio Range Over the Past 10 Years
Min: 3.81   Med: 47.44   Max: 66.39
Current: 42.5

During the past 4 years, Third Harmonic Bio's highest Current Ratio was 66.39. The lowest was 3.81. And the median was 47.44.

THRD's Current Ratio is ranked better than
98.27% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs THRD: 42.50

Third Harmonic Bio Current Ratio Historical Data

The historical data trend for Third Harmonic Bio's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio Current Ratio Chart

Third Harmonic Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Ratio
3.81 22.72 51.80 50.29

Third Harmonic Bio Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.00 50.29 66.10 41.13 42.50

Competitive Comparison of Third Harmonic Bio's Current Ratio

For the Biotechnology subindustry, Third Harmonic Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Third Harmonic Bio's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Third Harmonic Bio's Current Ratio distribution charts can be found below:

* The bar in red indicates where Third Harmonic Bio's Current Ratio falls into.



Third Harmonic Bio Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Third Harmonic Bio's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=272.446/5.418
=50.29

Third Harmonic Bio's Current Ratio for the quarter that ended in Sep. 2024 is calculated as

Current Ratio (Q: Sep. 2024 )=Total Current Assets (Q: Sep. 2024 )/Total Current Liabilities (Q: Sep. 2024 )
=300.232/7.065
=42.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Third Harmonic Bio  (NAS:THRD) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Third Harmonic Bio Current Ratio Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Third Harmonic Bio Business Description

Traded in Other Exchanges
N/A
Address
1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Executives
Edward R. Conner officer: Chief Medical Officer 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Julie Person officer: Chief Administrative Officer C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Natalie C. Holles director, officer: CEO C/O HYPERION THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE CA 94005
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022